Immunogenicity and Reactogenicity of 13-valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers and Children in Bobo-Dioulasso, Burkina Faso: a Phase 4 Randomized Trial
Phase of Trial: Phase IV
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Acronyms PCV13-Bobo
- 20 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 28 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 May 2014, according to ClinicalTrials.gov record.
- 28 Jan 2014 Status changed from not yet recruiting to active, no longer recruiting; according to ClinicalTrials.gov record.